JP2020521447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521447A5 JP2020521447A5 JP2019564782A JP2019564782A JP2020521447A5 JP 2020521447 A5 JP2020521447 A5 JP 2020521447A5 JP 2019564782 A JP2019564782 A JP 2019564782A JP 2019564782 A JP2019564782 A JP 2019564782A JP 2020521447 A5 JP2020521447 A5 JP 2020521447A5
- Authority
- JP
- Japan
- Prior art keywords
- drawings
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024109160A JP2024133640A (ja) | 2017-05-25 | 2024-07-05 | 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511010P | 2017-05-25 | 2017-05-25 | |
| US62/511,010 | 2017-05-25 | ||
| PCT/US2018/034655 WO2018218151A1 (en) | 2017-05-25 | 2018-05-25 | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024109160A Division JP2024133640A (ja) | 2017-05-25 | 2024-07-05 | 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521447A JP2020521447A (ja) | 2020-07-27 |
| JP2020521447A5 true JP2020521447A5 (enExample) | 2021-07-26 |
| JP7522426B2 JP7522426B2 (ja) | 2024-07-25 |
Family
ID=64397136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564782A Active JP7522426B2 (ja) | 2017-05-25 | 2018-05-25 | 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス |
| JP2024109160A Pending JP2024133640A (ja) | 2017-05-25 | 2024-07-05 | 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024109160A Pending JP2024133640A (ja) | 2017-05-25 | 2024-07-05 | 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11684637B2 (enExample) |
| EP (1) | EP3630144A4 (enExample) |
| JP (2) | JP7522426B2 (enExample) |
| KR (2) | KR20240132124A (enExample) |
| CN (1) | CN110891584B (enExample) |
| AU (1) | AU2018273963B2 (enExample) |
| BR (1) | BR112019024656A2 (enExample) |
| CA (1) | CA3064897A1 (enExample) |
| IL (1) | IL270876B2 (enExample) |
| WO (1) | WO2018218151A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| SG11202107904PA (en) * | 2019-01-24 | 2021-08-30 | University Of Central Florida Research Foundation Inc | Compositions and methods for stimulating natural killer cells |
| AU2020391178A1 (en) * | 2019-11-25 | 2022-06-09 | Ansun Biopharma, Inc. | Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| CN111676245B (zh) * | 2020-06-24 | 2022-09-13 | 武汉波睿达生物科技有限公司 | 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用 |
| AU2021324767A1 (en) * | 2020-08-12 | 2023-04-13 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for stimulating gamma delta T cells |
| CN112852757A (zh) * | 2021-02-01 | 2021-05-28 | 南京大学 | 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法 |
| AU2022255538B2 (en) * | 2021-04-08 | 2026-01-22 | Immvira Biopharmaceuticals Co., Limited | Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen |
| CN115678854A (zh) * | 2021-07-29 | 2023-02-03 | 上海中医药大学 | 一种基因工程细胞及其制备方法和应用 |
| CN116875547A (zh) * | 2023-09-04 | 2023-10-13 | 山东德升细胞治疗工程技术有限公司 | 一种利用细胞外泌体激活nk细胞的体外扩增培养方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1601438A (enExample) | 1968-10-17 | 1970-08-24 | ||
| US20020187543A1 (en) * | 2001-04-05 | 2002-12-12 | Curiel David T. | Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins |
| US20090214590A1 (en) * | 2005-07-08 | 2009-08-27 | Wayne State University | Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof |
| EP1945771A1 (en) | 2005-10-28 | 2008-07-23 | Novo Nordisk A/S | Fusion proteins that bind effector lymphocytes and target cells |
| CA2670790A1 (en) * | 2006-11-28 | 2008-06-05 | Ghc Research Development Corporation | Polypeptides comprising fas activation and nkg2d-ligand domains |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| WO2008140621A2 (en) * | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
| FR2938840B1 (fr) * | 2008-11-21 | 2010-12-17 | Centre Nat Rech Scient | Proteines mutantes de la proteine f de piv-5 et de piv-2 |
| BRPI0924123B8 (pt) | 2008-12-22 | 2021-05-25 | Oncos Therapeutics Oy | vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro |
| EP2485758A1 (en) * | 2009-10-09 | 2012-08-15 | New York Blood Center, Inc. | Immunopotentiator-linked oligomeric influenza immunogenic compositions |
| MY173638A (en) * | 2012-01-24 | 2020-02-12 | Univ Georgia | Parainfluenza virus 5 based vaccines |
| DK3578201T3 (da) * | 2012-06-28 | 2023-05-08 | Univ Of Central Florida Research Foundation Incorporated | Fremgangsmåder og sammensætninger til naturlige dræberceller |
| EP2892549A1 (en) | 2012-09-04 | 2015-07-15 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| WO2014041119A1 (en) * | 2012-09-14 | 2014-03-20 | Deutsches Krebsforschungszentrum | Oncolytic viruses expressing immuno-nucleases |
| PE20151921A1 (es) | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
| US20170007685A1 (en) * | 2013-11-05 | 2017-01-12 | The Board Of Regents Of The University Of Texas System | TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES |
| WO2015103438A2 (en) * | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| CA2960087C (en) | 2014-09-26 | 2024-02-27 | Bavarian Nordic A/S | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin |
| AU2015339447B2 (en) | 2014-10-27 | 2021-08-12 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for natural killer cells |
| HK1246180A1 (zh) | 2014-12-31 | 2018-09-07 | Celgene Corporation | 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法 |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| DK3288573T3 (da) * | 2015-04-30 | 2020-03-16 | Psioxus Therapeutics Ltd | Onkolytisk adenovirus, der koder for et b7-protein |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
-
2018
- 2018-05-25 CA CA3064897A patent/CA3064897A1/en active Pending
- 2018-05-25 AU AU2018273963A patent/AU2018273963B2/en active Active
- 2018-05-25 IL IL270876A patent/IL270876B2/en unknown
- 2018-05-25 BR BR112019024656A patent/BR112019024656A2/pt unknown
- 2018-05-25 CN CN201880047292.0A patent/CN110891584B/zh active Active
- 2018-05-25 KR KR1020247028510A patent/KR20240132124A/ko active Pending
- 2018-05-25 US US16/616,671 patent/US11684637B2/en active Active
- 2018-05-25 WO PCT/US2018/034655 patent/WO2018218151A1/en not_active Ceased
- 2018-05-25 JP JP2019564782A patent/JP7522426B2/ja active Active
- 2018-05-25 KR KR1020197037594A patent/KR102700175B1/ko active Active
- 2018-05-25 EP EP18806947.0A patent/EP3630144A4/en active Pending
-
2023
- 2023-05-15 US US18/317,616 patent/US12312393B2/en active Active
-
2024
- 2024-07-05 JP JP2024109160A patent/JP2024133640A/ja active Pending